Oxytocin
Oxytocin is a cyclic nonapeptide hormone from the hypothalamus, tied to social bonding, lactation, and stress modulation, but peptide communities discuss it almost exclusively for labor induction and postpartum care, where two-thirds of the six captured reports describe positive outcomes. Clinician-tier guidance calls for 200–300 mcg subcutaneously twice daily in one- to two-week cycles, though actual community posts rarely record specific dosing or timing. The central tradeoff is an off-label evidence base thinner than the discourse implies, with most exploratory indications lacking posted human results.
Research Evidence
Evidence shape
The evidence for oxytocin is moderate: the strongest trials reach Phase 3, and sixteen indications have posted results, led by schizophrenia, alcohol use disorder, and healthy-volunteer pharmacokinetic studies. The registry spans 160 distinct conditions across 102 sponsors, yet only 38 blinded trials have posted data, leaving most of the landscape exploratory. More than 120 indications are single-trial entries without replication, and fourteen registered areas—including knee osteoarthritis, postoperative pain, and COVID-19—have no posted results.
Anecdotal efficacy
Side effects
Clinical research side effects
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How Oxytocin is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
- Timing
- unspecified
- Cycle
- unspecified
157 completed trials identified; trial dosing not reliably extracted from registry data.
- Frequency
- BID
- Timing
- unspecified
- Route
- subQ
- Cycle
- unspecified
Clinician protocols dose 200 µg–300 µg BID subQ (1 source).
No structured protocol details captured for this tier yet.
Community discussions primarily focus on Oxytocin's role in labor induction and postpartum care. Of 6 reports, 66.7% were positive, while 33.3% were negative. Specific dosing details were not consistently reported in these discussions.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Regulatory safety notes
- • CONTRAINDICATIONS Antepartum use of Pitocin is contraindicated in any of the following circumstances: Where there is significant cephalopelvic disproportion; In unfavorable fetal positions or presentations, such as tran…
- • patients with hypersensitivity to the drug.
- • Drug Interactions Severe hypertension has been reported when oxytocin was given three to four hours following prophylactic administration of a vasoconstrictor in conjunction with caudal block anesthesia. Cyclopropane anesthesia may modify oxytocin's cardiovas…
Peptide feedback
0 forum repliesLive community discussion for Oxytocin, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.